TRS Stock Analysis: TriMas | NASDAQ
Packaging & Containers | NASDAQ, USA | Market Cap: 1.372m USD | 12M Return: 4.9% | US8962152091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.1M
EPS Trend: 27.1%
Qual. Beats: 0
Rev. Trend: -64.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
TriMas Corporation (NASDAQ: TRS) is a U.S.-based diversified manufacturer that designs, develops, and sells products serving three end markets: consumer products, aerospace and defense, and industrial customers worldwide. The company operates through two reportable segments - Packaging and Specialty Products - and sells through a mix of direct sales, third-party agents, and distributors. Headquartered in Bloomfield Hills, Michigan, TriMas was incorporated in 1986 and trades as a small-cap stock in the GICS Industrials sector.
The Packaging segment is the larger and more diversified of the two businesses, producing dispensing solutions (foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume and trigger sprayers), a wide range of polymeric and steel caps and closures (food lids, flip-top and beverage closures, child-resistant caps, drum and pail closures, and flexible spouts), polymeric jar products, integrated dispensers, bag-in-box systems, and consumable vascular delivery and diagnostic test components. These products are marketed under a portfolio of established brands - Rieke, Taplast, Affaba & Ferrari, Aarts Packaging, Intertech, Omega Plastics, and Rapak - reflecting a common specialty-packaging strategy of maintaining multiple brand identities to serve varied regional markets, customer specifications, and application niches.
The Specialty Products segment, operating under the Norris Cylinder brand, designs, manufactures, and distributes steel cylinders used to transport, store, and dispense packaged and compressed gases. These cylinders are safety-critical, pressure-bearing products typically subject to stringent regulatory standards and third-party certifications, which tend to create meaningful barriers to entry and support long product life cycles in the specialty gas supply chain.
TriMass business model combines engineered, proprietary components with broad brand coverage across packaging formats and one niche industrial product line. This structure provides diversification across end markets and geographies while concentrating the company in relatively defensible specialty niches within the broader industrial and packaging landscape.
- Aerospace and defense demand drives Norris Cylinder revenue growth
- Resin and raw material costs pressure Packaging segment margins
- Acquisitions expand product portfolio in dispensing and specialty packaging
| Net Income: 905.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.42 > 0.02 and ΔFCF/TA 38.30 > 1.0 |
| NWC/Revenue: 164.5% < 20% (prev 37.25%; Δ 127.3% < -1%) |
| CFO/TA 0.09 > 3% & CFO 195.7m > Net Income 905.2m |
| Net Debt (-763.8m) to EBITDA (149.4m): -5.11 < 3 |
| Current Ratio: 5.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.2m) vs 12m ago -11.53% < -2% |
| Gross Margin: 21.59% > 18% (prev 20.78%; Δ 0.81% > 0.5%) |
| Asset Turnover: 41.59% > 50% (prev 55.78%; Δ -14.19% > 0%) |
| Interest Coverage Ratio: 2.92 > 6 (EBIT TTM 53.4m / Interest Expense TTM 18.3m) |
| A: 0.56 (Total Current Assets 1.55b - Total Current Liabilities 284.2m) / Total Assets 2.25b |
| B: 0.41 (Retained Earnings 917.0m / Total Assets 2.25b) |
| C: 0.03 (EBIT TTM 53.4m / Avg Total Assets 1.85b) |
| D: 1.80 (Book Value of Equity 1.44b / Total Liabilities 803.0m) |
| Altman-Z'' = 7.10 = AAA |
| DSRI: 0.79 (Receivables 153.6m/203.8m, Revenue 767.6m/806.3m) |
| GMI: 0.96 (GM 20.78% / 21.59%) |
| AQI: 0.47 (AQ_t 0.19 / AQ_t-1 0.40) |
| SGI: 0.95 (Revenue 767.6m / 806.3m) |
| TATA: 0.32 (NI 905.2m - CFO 195.7m) / TA 2.25b) |
| Beneish M = -3.54 (Cap -4..+1) = AAA |
As of October 12, 2026, the stock is trading at USD 38.15 with a total of 207,053 shares traded. Over the past week, the price has changed by -2.48%, over one month by -0.24%, over three months by -7.94% and over the past year by +4.88%.
Current recommended Stop Loss: 36.90 (which is 3.3% or 1.4 ATR below the current price).
TriMas has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy TRS.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 45 | 18% |
P/E Trailing = 15.8714
P/E Forward = 19.3424
P/S = 2.0654
P/B = 0.9748
P/EG = 1.9395
Revenue TTM = 767.6m USD
EBIT TTM = 53.4m USD
EBITDA TTM = 149.4m USD
Long Term Debt = 396.9m USD (from longTermDebt, last quarter)
Short Term Debt = 8.01m USD (from shortTermDebt, last quarter)
Debt = 478.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 40.9m
Net Debt = -763.8m USD (calculated: Debt 478.6m - CCE 1.24b)
Enterprise Value = 608.3m USD (1.37b + Debt 478.6m - CCE 1.24b)
Interest Coverage Ratio = 2.92 (Ebit TTM 53.4m / Interest Expense TTM 18.3m)
EV/FCF = 0.65x (Enterprise Value 608.3m / FCF TTM 939.0m)
FCF Yield = 154.3% (FCF TTM 939.0m / Enterprise Value 608.3m)
FCF Margin = 122.3% (FCF TTM 939.0m / Revenue TTM 767.6m)
Net Margin = 117.9% (Net Income TTM 905.2m / Revenue TTM 767.6m)
Gross Margin = 21.59% ((Revenue TTM 767.6m - Cost of Revenue TTM 601.9m) / Revenue TTM)
Gross Margin QoQ = 20.24% (prev 21.03%)
Tobins Q-Ratio = 0.27 (Enterprise Value 608.3m / Total Assets 2.25b)
Interest Expense / Debt = 3.83% (Interest Expense 18.3m / Debt 478.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 42.2m (EBIT 53.4m * (1 - 21.00%))
Current Ratio = 3.05 (Total Current Assets 1.55b / Total Current Liabilities 507.6m)
Debt / Equity = 0.33 (Debt 478.6m / totalStockholderEquity, last quarter 1.44b)
Debt / EBITDA = -5.11 (Net Debt -763.8m / EBITDA 149.4m)
Debt / FCF = -0.81 (Net Debt -763.8m / FCF TTM 939.0m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 49.05% (Net Income 905.2m / Total Assets 2.25b)
RoE = 83.76% (Net Income TTM 905.2m / Total Stockholder Equity 1.08b)
RoCE = 3.62% (EBIT 53.4m / Capital Employed (Equity 1.08b + L.T.Debt 396.9m))
RoIC = 2.19% (NOPAT 42.2m / Invested Capital 1.93b)
WACC = 7.25% (E(1.37b)/V(1.85b) * Re(8.73%) + D(478.6m)/V(1.85b) * Rd(3.83%) * (1-Tc(0.21)))
Discount Rate = 8.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.41 | Cagr: -5.70%
[DCF] Terminal Value 77.97% ; FCFF base≈583.6m ; Y1≈669.1m ; Y5≈984.7m
[DCF] Fair Price = 434.3 (EV 14.8b - Net Debt -763.8m = Equity 15.6b / Shares 35.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 27.11 | EPS CAGR: 2.64% | SUE: 0.36 | # QB: 0
Revenue Correlation: -64.75 | Revenue CAGR: -4.25% | SUE: -0.03 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.48 | Chg30d=+0.00% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=1.65 | Chg30d=+0.00% | Revisions=-40% | GrowthEPS=-21.0% | GrowthRev=-35.0%
EPS next Year (2027-12-31): EPS=2.13 | Chg30d=+0.71% | Revisions=+25% | GrowthEPS=+28.9% | GrowthRev=+2.8%
[Analyst] Revisions Ratio: -38% (up=1, down=4)